MeSH term
Frequency | Condition_Probility | Cell Line, Tumor | 3 | 0.0 |
Humans | 57 | 0.0 |
Octreotide/*pharmacology | 2 | 9.0 |
Receptors, Somatostatin/metabolism | 2 | 11.0 |
Adenylate Cyclase/metabolism | 5 | 3.0 |
Animals | 31 | 0.0 |
Cell Line | 9 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Hamsters | 6 | 0.0 |
Receptors, Somatostatin/*metabolism | 6 | 25.0 |
Research Support, Non-U.S. Gov't | 43 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Signal Transduction | 8 | 0.0 |
Blotting, Western | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Adult | 13 | 0.0 |
Aged | 13 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Child | 3 | 0.0 |
*Gene Expression | 5 | 0.0 |
Middle Aged | 14 | 0.0 |
Receptors, Somatostatin/*genetics/metabolism | 2 | 22.0 |
Amino Acid Sequence | 13 | 0.0 |
Gene Expression | 5 | 0.0 |
Molecular Sequence Data | 21 | 0.0 |
Receptors, Somatostatin/genetics/*metabolism | 4 | 30.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Female | 14 | 0.0 |
Male | 14 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Cell Division | 2 | 0.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Piperazines/pharmacology | 2 | 1.0 |
Receptors, Somatostatin/*physiology | 2 | 33.0 |
Somatostatin/*analogs & derivatives/pharmacology | 2 | 16.0 |
Receptors, Somatostatin/*genetics | 8 | 29.0 |
Comparative Study | 4 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
In Vitro | 3 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Receptors, Somatostatin/*biosynthesis | 4 | 57.0 |
Base Sequence | 14 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Receptors, Somatostatin/*genetics/*metabolism | 2 | 66.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Receptors, Somatostatin/classification/*metabolism | 3 | 100.0 |
Octreotide/pharmacology | 3 | 12.0 |
Pituitary Neoplasms/*metabolism | 2 | 5.0 |
Adenylate Cyclase Toxin | 5 | 20.0 |
CHO Cells | 5 | 0.0 |
Transfection | 3 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 5 | 2.0 |
Cell Division/drug effects | 2 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
GTP-Binding Proteins/metabolism | 4 | 1.0 |
*Adenoma | 2 | 100.0 |
*Pituitary Neoplasms | 2 | 66.0 |
Rats | 6 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Somatostatin/*analogs & derivatives/*pharmacology | 2 | 22.0 |
Somatostatin/metabolism | 3 | 6.0 |
Substrate Specificity | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
RNA-Directed DNA Polymerase | 3 | 2.0 |
Mice | 8 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Autoradiography | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Octreotide/metabolism | 2 | 50.0 |
Cloning, Molecular | 8 | 0.0 |
Receptors, Somatostatin/*analysis | 2 | 25.0 |
DNA, Complementary | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
*Signal Transduction | 2 | 0.0 |
Somatostatin/analogs & derivatives/*pharmacology | 2 | 66.0 |
Pertussis Toxin | 4 | 2.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 2 | 1.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Somatostatin/pharmacology | 2 | 4.0 |
DNA | 2 | 0.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology | 2 | 2.0 |
Receptors, Somatostatin/drug effects/genetics/*metabolism | 2 | 40.0 |
Receptors, Somatostatin | 2 | 13.0 |
Blotting, Southern | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
